|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Liu M, Sakamaki T, Casimiro MC, Willmarth
NE, Quong AA, Ju X, Ojeifo J, Jiao X, Yeow WS, Katiyar S, et al:
The canonical NF-kappaB pathway governs mammary tumorigenesis in
transgenic mice and tumor stem cell expansion. Cancer Res.
70:10464–10473. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
He M, Fu Y, Yan Y, Xiao Q, Wu H, Yao W,
Zhao H, Zhao L, Jiang Q, Yu Z, et al: The Hedgehog signalling
pathway mediates drug response of MCF-7 mammosphere cells in breast
cancer patients. Clin Sci (Lond). 129:809–822. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ibrahim SA, Gadalla R, El-Ghonaimy EA,
Samir O, Mohamed HT, Hassan H, Greve B, El-Shinawi M, Mohamed MM
and Götte M: Syndecan-1 is a novel molecular marker for triple
negative inflammatory breast cancer and modulates the cancer stem
cell phenotype via the IL-6/STAT3, Notch and EGFR signaling
pathways. Mol Cancer. 16:572017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jang GB, Kim JY, Cho SD, Park KS, Jung JY,
Lee HY, Hong IS and Nam JS: Blockade of Wnt/b-catenin signaling
suppresses breast cancer metastasis by inhibiting CSC-like
phenotype. Sci Rep. 5:124652015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang G, Chan CH, Gao Y and Lin HK: Novel
roles of Skp2 E3 ligase in cellular senescence, cancer progression
and metastasis. Chin J Cancer. 31:169–177. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Frescas D and Pagano M: Deregulated
proteolysis by the F-box proteins SKP2 and beta-TrCP: Tipping the
scales of cancer. Nat Rev Cancer. 8:438–449. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang Z, Liu P, Inuzuka H and Wei W: Roles
of F-box proteins in cancer. Nat Rev Cancer. 14:233–247. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chan CH, Morrow JK, Zhang S and Lin HK:
Skp2: A dream target in the coming age of cancer therapy. Cell
Cycle. 13:679–680. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang W, Cao L, Sun Z, Xu J, Tang L, Chen
W, Luo J, Yang F, Wang Y and Guan X: Skp2 is over-expressed in
breast cancer and promotes breast cancer cell proliferation. Cell
Cycle. 15:1344–1351. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yang C, Nan H, Ma J, Jiang L, Guo Q, Han
L, Zhang Y, Nan K and Guo H: High Skp2/Low p57(Kip2) expression is
associated with poor prognosis in human breast carcinoma. Breast
Cancer (Auckl). 9 Suppl 1:S13–S21. 2015.
|
|
12
|
Wang Z, Fukushima H, Inuzuka H, Wan L, Liu
P, Gao D, Sarkar FH and Wei W: Skp2 is a promising therapeutic
target in breast cancer. Front Oncol. 1:2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Messina M, Nagata C and Wu AH: Estimated
Asian adult soy protein and isoflavone intakes. Nutr Cancer.
55:1–12. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pavese JM, Farmer RL and Bergan RC:
Inhibition of cancer cell invasion and metastasis by genistein.
Cancer Metastasis Rev. 29:465–482. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Choi YH, Zhang L, Lee WH and Park KY:
Genistein-induced G2/M arrest is associated with the inhibition of
cyclin B1 and the induction of p21 in human breast carcinoma cells.
Int J Oncol. 13:391–396. 1998.PubMed/NCBI
|
|
16
|
Valachovicova T, Slivova V, Bergman H,
Shuherk J and Sliva D: Soy isoflavones suppress invasiveness of
breast cancer cells by the inhibition of NF-kappaB/AP-1-dependent
and -independent pathways. Int J Oncol. 25:1389–1395.
2004.PubMed/NCBI
|
|
17
|
Li Y, Chen H, Hardy TM and Tollefsbol TO:
Epigenetic regulation of multiple tumor-related genes leads to
suppression of breast tumorigenesis by dietary genistein. PLoS One.
8:e543692013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bonofiglio D, Giordano C, De Amicis F,
Lanzino M and Andò S: Natural products as promising antitumoral
agents in breast cancer: Mechanisms of action and molecular
targets. Mini Rev Med Chem. 16:596–604. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nagata C, Mizoue T, Tanaka K, Tsuji I,
Tamakoshi A, Matsuo K, Wakai K, Inoue M, Tsugane S, Sasazuki S, et
al: Soy intake and breast cancer risk: an evaluation based on a
systematic review of epidemiologic evidence among the Japanese
population. Jpn J Clin Oncol. 44:282–295. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Uifalean A, Schneider S, Ionescu C, Lalk M
and Iuga CA: Soy Isoflavones and breast cancer cell lines:
Molecular mechanisms and future perspectives. Molecules.
21:E132015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sarkar FH and Li Y: Mechanisms of cancer
chemoprevention by soy isoflavone genistein. Cancer Metastasis Rev.
21:265–280. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang TT, Sathyamoorthy N and Phang JM:
Molecular effects of genistein on estrogen receptor mediated
pathways. Carcinogenesis. 17:271–275. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Akiyama T, Ishida J, Nakagawa S, Ogawara
H, Watanabe S, Itoh N, Shibuya M and Fukami Y: Genistein, a
specific inhibitor of tyrosine-specific protein kinases. J Biol
Chem. 262:5592–5595. 1987.PubMed/NCBI
|
|
24
|
Corbett AH, Hong D and Osheroff N:
Exploiting mechanistic differences between drug classes to define
functional drug interaction domains on topoisomerase II. Evidence
that several diverse DNA cleavage-enhancing agents share a common
site of action on the enzyme. J Biol Chem. 268:14394–14398.
1993.PubMed/NCBI
|
|
25
|
Shafiee G, Saidijam M, Tavilani H,
Ghasemkhani N and Khodadadi I: Genistein induces apoptosis and
inhibits proliferation of HT29 colon cancer cells. Int J Mol Cell
Med. 5:178–191. 2016.PubMed/NCBI
|
|
26
|
Wang SD, Chen BC, Kao ST, Liu CJ and Yeh
CC: Genistein inhibits tumor invasion by suppressing multiple
signal transduction pathways in human hepatocellular carcinoma
cells. BMC Complement Altern Med. 14:262014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhao Q, Zhao M, Parris AB, Xing Y and Yang
X: Genistein targets the cancerous inhibitor of PP2A to induce
growth inhibition and apoptosis in breast cancer cells. Int J
Oncol. 49:1203–1210. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen Q, Xie W, Kuhn DJ, Voorhees PM,
Lopez-Girona A, Mendy D, Corral LG, Krenitsky VP, Xu W, Moutouh-de
Parseval L, et al: Targeting the p27 E3 ligase SCF(Skp2) results in
p27- and Skp2-mediated cell-cycle arrest and activation of
autophagy. Blood. 111:4690–4699. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chan CH, Morrow JK, Li CF, Gao Y, Jin G,
Moten A, Stagg LJ, Ladbury JE, Cai Z, Xu D, et al: Pharmacological
inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem
cell traits and cancer progression. Cell. 154:556–568. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jandial DD, Krill LS, Chen L, Wu C, Ke Y,
Xie J, Hoang BH and Zi X: Induction of G2M arrest by flavokawain A,
a kava chalcone, increases the responsiveness of
her2-overexpressing breast cancer cells to herceptin. Molecules.
22:2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Huang C, Wei YX, Shen MC, Tu YH, Wang CC
and Huang HC: Chrysin, abundant in morinda citrifolia fruit
water-etoac extracts, combined with apigenin synergistically
induced apoptosis and inhibited migration in human breast and liver
cancer cells. J Agric Food Chem. 64:4235–4245. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Su J, Zhou X, Wang L, Yin X and Wang Z:
Curcumin inhibits cell growth and invasion and induces apoptosis
through down-regulation of Skp2 in pancreatic cancer cells. Am J
Cancer Res. 6:1949–1962. 2016.PubMed/NCBI
|
|
33
|
Feng S, Wang Y, Zhang R, Yang G, Liang Z,
Wang Z and Zhang G: Curcumin exerts its antitumor activity through
regulation of miR-7/Skp2/p21 in nasopharyngeal carcinoma cells.
Onco Targets Ther. 10:2377–2388. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Huang MH, Lin SZ, Lin PC, Chiou TW, Harn
YW, Ho LI, Chan TM, Chou CW, Chuang CH, Su HL and Harn HJ: Brain
tumor senescence might be mediated by downregulation of S-phase
kinase-associated protein 2 via butylidenephthalide leading to
decreased cell viability. Tumour Biol. 35:4875–4884. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yin X, Zhang Y, Su J, Hou Y, Wang L, Ye X,
Zhao Z, Zhou X, Li Y and Wang Z: Rottlerin exerts its anti-tumor
activity through inhibition of Skp2 in breast cancer cells.
Oncotarget. 7:66512–66524. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Su J, Wang L, Yin X, Zhao Z, Hou Y, Ye X,
Zhou X and Wang Z: Rottlerin exhibits anti-cancer effect through
inactivation of S phase kinase-associated protein 2 in pancreatic
cancer cells. Am J Cancer Res. 6:2178–2191. 2016.PubMed/NCBI
|
